Literature DB >> 8926287

Transplant-associated autoimmune mechanisms in human hepatitis C virus infection.

K Zucker1, D Roth, R Cirocco, J Mathew, M Carreno, L Fuller, T Karatzas, Y Jin, G Burke, J Nery, M Webb, A Tzakis, V Esquenazi, J Miller.   

Abstract

In order to define factors which are important for the development of hepatitis C virus (HCV) infection and disease in transplant patients, we examined the role of class II MHC antigen restriction in viral antigen presentation to support a hypothesis of the association of this disease with an autoimmune pathogenesis. A greater degree of histocompatibility match between these donors and their HCV-negative recipients was associated with a greater predisposition to recipient HCV liver disease (ALT elevation) posttransplant. The HCV carrier state could be identified with significant amplification of autologous mixed lymphocyte reactivity (AMLR) in both long-term hemodialysis and long-term renal transplant patients, but the AMLR was absent in end-stage liver disease patients with HCV-associated cirrhosis and was insignificantly elevated in these patients with persistent infection in the first 2 years after a new liver was transplanted. There was also a moderate reduction in autologous reactivity as well as serum HCV titers among renal transplant patients who displayed biochemical evidence of chronic liver disease as opposed to those who did not. This appeared later in the course of the disease. HCV RNA could be detected in peripheral blood mononuclear cells (PBMC) of only a portion of HCV-infected renal transplant patients and these showed significantly higher autologous reactivity. In contrast, despite the fact that observations were earlier after de novo liver transplantation, HCV RNA (i.e., earlier in the course of a new or recurrent disease process) was found in PBMC of all liver transplant recipients tested. The AMLR of noninfected laboratory volunteers could be amplified by preincubating their stimulating cells (APCs) with enriched HCV possibly in immune complex (pHCV-IC). This amplification appeared only with specific combinations of HCV strains with HLA DR serotypes. In addition, HCV-primed T cells could be generated to the virus which displayed accelerated activation kinetics. Liver infiltrating lymphocytes extracted from HCV-positive end-stage diseased livers had significantly higher proliferative and cytotoxic reactivity to autologous (HCV-infected) hepatocytes than the extracted lymphocytes responding to autologous hepatocytes from HCV-negative livers. These findings offer evidence of dynamic autoimmune mechanisms in the spectrum of progression of HCV disease and may help to predict the effect of intervention at various intervals in this progression in organ transplant recipients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8926287     DOI: 10.1007/bf01540974

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  29 in total

1.  Hepatitis C virus infection among kidney transplant recipients.

Authors:  E Ponz; J M Campistol; M Bruguera; J M Barrera; C Gil; J B Pinto; J Andreu
Journal:  Kidney Int       Date:  1991-10       Impact factor: 10.612

2.  The temporal association between gamma delta T cells and the natural history of insulin-dependent diabetes.

Authors:  F P Lang; B H Pollock; W J Riley; N K Maclaren; D J Barrett
Journal:  J Autoimmun       Date:  1993-02       Impact factor: 7.094

3.  CD8+/DR+ T gamma cells inhibit the autologous mixed lymphocyte reaction.

Authors:  M K Haynes; J Miller; L Fuller
Journal:  Clin Exp Immunol       Date:  1990-10       Impact factor: 4.330

4.  Detection of antibody to hepatitis C virus in renal transplant recipients.

Authors:  D Roth; J A Fernandez; G W Burke; V Esquenazi; J Miller
Journal:  Transplantation       Date:  1991-02       Impact factor: 4.939

Review 5.  Autoimmune disease and the major histocompatibility complex: therapeutic implications.

Authors:  T A Dalton; J C Bennett
Journal:  Am J Med       Date:  1992-02       Impact factor: 4.965

6.  Depletion of hepatitis C virus from procured kidneys using pulsatile perfusion preservation.

Authors:  K Zucker; R Cirocco; D Roth; L Olson; G W Burke; J Nery; V Esquenazi; J Miller
Journal:  Transplantation       Date:  1994-03-27       Impact factor: 4.939

7.  Induction of cytotoxic T cells to a cross-reactive epitope in the hepatitis C virus nonstructural RNA polymerase-like protein.

Authors:  M Shirai; T Akatsuka; C D Pendleton; R Houghten; C Wychowski; K Mihalik; S Feinstone; J A Berzofsky
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

8.  Late mortality and morbidity five to eighteen years after kidney transplantation.

Authors:  C Toussaint; P Kinnaert; P Vereerstraeten
Journal:  Transplantation       Date:  1988-03       Impact factor: 4.939

9.  Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay.

Authors:  L Stuyver; R Rossau; A Wyseur; M Duhamel; B Vanderborght; H Van Heuverswyn; G Maertens
Journal:  J Gen Virol       Date:  1993-06       Impact factor: 3.891

10.  Liver disease in recipients of long-functioning renal allografts.

Authors:  M R Weir; R L Kirkman; T B Strom; N L Tilney
Journal:  Kidney Int       Date:  1985-11       Impact factor: 10.612

View more
  2 in total

1.  The effects of chimeric cells following donor bone marrow infusions as detected by PCR-flow assays in kidney transplant recipients.

Authors:  R Garcia-Morales; M Carreno; J Mathew; K Zucker; R Cirocco; G Ciancio; G Burke; D Roth; D Temple; A Rosen; L Fuller; V Esquenazi; T Karatzas; C Ricordi; A Tzakis; J Miller
Journal:  J Clin Invest       Date:  1997-03-01       Impact factor: 14.808

2.  The immune reactivity role of HCV-induced liver infiltrating lymphocytes in hepatocellular damage.

Authors:  Y Jin; L Fuller; M Carreno; K Zucker; D Roth; V Esquenazi; T Karatzas; S J Swanson; A G Tzakis; J Miller
Journal:  J Clin Immunol       Date:  1997-03       Impact factor: 8.542

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.